Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Masatoshi Eto Last modified date:2020.07.14

Professor / Department of Urology, Graduate School of Medical Sciences / Department of Clinical Medicine / Faculty of Medical Sciences


Papers
1. Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer., Anticancer Res, 39 (6): 3191-3195, 2019.06.
2. Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y:, MicroRNA‐204‐5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma., Cancer Sci, 110 (6): 1897-1908, 2019.06.
3. Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men., Clin Genitourin Cancer, 17 (3): e387-e393, 2019.06.
4. Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer:, Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma., Cancer Sci, 110 (6): 1820-1828, 2019.06.
5. Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study., Jpn J Clin Oncol, 49 (6): 506-514, 2019.06.
6. Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men., Cancer Chemother Pharmacol, 83 (5): 933-938, 2019.05.
7. Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H:, Overview of current and future systemic therapy for metastatic renal cell carcinoma., Jpn J Clin Oncol, 49 (5): 395-403, 2019.05.
8. Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, Eto M:, Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle., Low Urin Tract Symptoms, 11 (2): O209-O217, 2019.04.
9. Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ:, Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale., Future Oncol, 15 (9): 929-941, 2019.03.
10. Shiota M, Namitome R, Kobayashi T, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer., Int J Urol, 26 (3): 426-428, 2019.03.
11. Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer., Urol Oncol, 37 (3): 180.e19-180.e24, 2019.03.
12. Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M:, Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study., Med Oncol, 36 (4): 32, 2019.02.
13. Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M:, Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone., JAMA Netw Open, 2 (2): e190115, 2019.02.
14. Murakami Y, Naganuma H, Tanigawa S, Fujimori T, Eto M, Nishinakamura R:, Reconstitution of the embryonic kidney identifies a donor cell contribution to the renal vasculature upon transplantation., Sci Rep, 9 (1): 1172, 2019.02.
15. Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, Eto M, Tamada K:, Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment., Cancer Immunol Immunother, 68 (2): 201-211, 2019.02.
16. Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H:, Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan., Int J Urol, 26 (2): 202-210, 2019.02.
17. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy., Front Oncol, 8: 635, 2018, 2018.12.
18. Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI:, Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial., Ann Oncol 29, 29 (12): 2371-2378, 2018, 2018.12.
19. Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T:, Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan., Clin Genitourin Cancer, 16 (6): e1201-e1214, 2018, 2018.12.
20. Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer., Andrologia, 50 (10): e13119, 2018, 2018.12.
21. Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:, Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy., Mol Clin Oncol 9 (5): 575-581, 2018, 9 (5): 575-581, 2018, 2018.11.
22. Takahashi R, Kimoto Y, Eto M:, Long-term urodynamic follow-up after external sphincterotomy in patients with spinal cord injury., Neurourol Urodyn, 37 (8): 2625-263, 2018, 2018.11.
23. Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y:, Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor., J Cancer, 9 (23): 4440-4448, 2018, 2018.10.
24. Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants., Cancer Sci, 109 (10): 3224-3234, 2018, 2018.10.
25. Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone., Prostate Int, 6 (3): 104-109,2018, 2018.09.
26. Inoue M, Okamura K, Kitaoka C, Kinoshita F, Namitome R, Nakamura U, Shiota M, Goto K, Ohtsubo T, Matsumura K, Oda Y, Eto M, Kitazono T:, Metyrapone-responsive ectopic ACTH-secreting pheochromocytoma with a vicious cycle via a glucocorticoid-driven positive-feedback mechanism., Endocr J, 65 (7): 755-767, 2018, 2018.07.
27. Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:, Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget, 9 (55): 30587-30593, 2018, 2018.07.
28. Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:, Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer., Anticancer Res, 38 (7): 4115-4121, 2018, 2018.07.
29. Akitake M, Kiyoshima K, Yokomizo A, Shiga K, Koga H, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Yamaguchi A, Eto M:, A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: A retrospective analysis of 245 cases., Mol Clin Oncol, 8 (6): 785-790, 2018, 2018.06.
30. Morizane S, Honda M, Fukasawa S, Komaru A, Inokuchi J, Eto M, Shimbo M, Hattori K, Kawano Y, Takenaka A:, Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan., Int J Clin Oncol, 23 (3): 568-575, 2018, 2018.06.
31. Reix B, Bernhard JC, Patard JJ, Bigot P, Villers A, Suer E, Vuong NS, Verhoest G, Alimi Q, Beauval JB, Benoit T, Nouhaud FX, Lenormand C, Hamidi N, Cai J, Eto M, Larre S, El Bakhri A, Ploussard G, Hung A, Koutlidis N, Schneider A, Carrouget J, Droupy S, Marchal S, Doerfler A, Seddik S, Matsugasumi T, Orsoni X, Descazeaud A, Pfister C, Bensalah K, Soulie M, Gill I, Flamand V; Kidney Cancer group of the CCAFU:, Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR., Prog Urol, 28 (3): 146-155, 2018, 2018.03.
32. Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer., J Urol, 199 (3): 734-740, 2018, 2018.03.
33. Takeuchi A, Kato K, Akashi K, Eto M:, Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy., Int J Urol, 25 (2): 112-120, 2018, 2018.02.
34. Tsuruta M, Ueda S, Yew PY, Fukuda I, Yoshimura S, Kishi H, Hamana H, Hirayama M, Yatsuda J, Irie A, Senju S, Yuba E, Kamba T, Eto M, Nakayama H, Nishimura Y:, Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4+ T cells expressing converged T-cell receptor genes in vitro., Oncoimmunology, 7 (4): e1415687, 2018, 2018.01.
35. Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M:, Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study)., Low Urin Tract Symptoms, 10 (1): 76-83, 2018, 2018.01.
36. Fujimoto N, Kubo T, Hisaoka M, Udo K, Yokomizo A, Shibuya T, Wakeda H, Nishihara K, Moriya R, Iwakuma K; Kyushu Cooperative Urological Research Group:, Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan., Int J Urol, 25 (1): 61-67, 2018, 2018.01.
37. Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association., Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 47 (12): 1162-1169, 2017, 2017.12.
38. Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S; Japan Public Health Center-based Prospective Study Group:, Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study., Int J Cancer, 141 (12): 2480-2488, 2017, 2017.12.
39. Matsumoto T, Uchiumi T, Monji K, Yagi M, Setoyama D, Amamoto R, Matsushima Y, Shiota M, Eto M, Kang D:, Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity., Oncogenesis, 6 (11): 397, 2017, 2017.11.
40. Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, Mizusawa J, Eba J, Naito S:, Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A., World J Urol, 35 (11): 1737-1744, 2017, 2017.11.
41. Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer., Anticancer Res, 37 (10): 5631-5637, 2017, 2017.10.
42. Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M:, Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models., Cancer Sci, 108 (10): 1974-1984, 2017, 2017.10.
43. Yamaguchi K, Inoue T, Habuchi T, Inokuchi J, Yokomizo A, Eto M, Kanayama HO:, An In Vitro Study of a New Device: Evaluation of Novel Wide-Angle Lens Flexible Cystoscope Using Phantom Bladder Model., J Endourol, 31 (10): 1073-1078, 2017, 2017.10.
44. Masaoka H, Gallus S, Ito H, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Aldehyde Dehydrogenase 2 Polymorphism Is a Predictor of Smoking Cessation., Nicotine Tob Res, 19 (9): 1087-1094, 2017, 2017.09.
45. Masaoka H, Ito H, Yokomizo A, Eto M, Matsuo K:, Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan., Cancer Sci , 108 (8): 1673-1680, 2017, 2017.08.
46. Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I:, Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment., Ann Oncol, 28 (8): 2038-2039, 2017, 2017.08.
47. Inokuchi J, Eto M, Hara T, Fujimoto H, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C; Cancer Registration Committee of the Japanese Urological Association:, Impact of lymph node dissection on clinical outcomes during nephroureterectomy in patients with clinically node-negative upper urinary tract urothelial cancer: subanalysis of a multi-institutional nationwide case series of the Japanese Urological Association., Jpn J Clin Oncol, 47 (7): 652-659, 2017, 2017.07.
48. Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S:, Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study., Jpn J Clin Oncol, 47 (7): 639-646, 2017, 2017.07.
49. Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Koga H, Yamaguchi A, Naito S, Eto M:, Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy., Jpn J Clin Oncol, 47 (5): 453-457, 2017, 2017.05.
50. Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A, Eto M:, The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer., Ann Surg Oncol, 24 (5): 1443-1450, 2017, 2017.05.
51. Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer., Endocr Relat Cancer, 24 (4): 171-180, 2017, 2017.04.
52. Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T:, A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder., Ann Oncol, 28 (4): 798-803, 2017, 2017.04.
53. Masaoka H, Ito H, Gallus S, Watanabe M, Yokomizo A, Eto M, Matsuo K:, Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population., Drug Alcohol Depend, 173: 85-91, 2017, 2017.04.
54. Shiota M, Fujimoto N, Itsumi M, Takeuchi A, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress., Ann Oncol, 28 (3): 569-575, 2017, 2017.03.
55. Tatsugami K, Yoshioka K, Shiroki R, Eto M, Yoshino Y, Tozawa K, Fukasawa S, Fujisawa M, Takenaka A, Nasu Y, Kashiwagi A, Gotoh M, Terachi T; Japanese Society of Endourology:, Reality of nerve sparing and surgical margins in surgeons' early experience with robot-assisted radical prostatectomy in Japan., Int J Urol, 24 (3): 191-196, 2017, 2017.03.
56. Imada K, Shiota M, Kuroiwa K, Sugimoto M, Abe T, Kohashi K, Yokomizo A, Eto M, Naito S, Oda Y:, FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer., Prostate, 77 (2): 145-153, 2017, 2017.02.
57. Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M:, Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor., J Urol, 197 (2): 308-313, 2017, 2017.02.
58. Bigot P, Bernhard JC, Flamand V, Gill I, Verhoest G, Beauval JB, Nouhaud FX, Suer E, Ploussard G, Hetet JF, Rigaud J, Baco E, Larré S, Sebe P, Koutlidis N, Descazeaud A, Eto M, Doerfler A, Roupret M, Vuong NS, Reix B, Matsugasumi T, Bakri AE, Albiges L, Soulié M, Patard JJ, Méjean A, Bensalah K; members of the Kidney Cancer group of the CCAFU:, Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes., Urol Oncol, 35 (1): 35.e15-35.e19, 2017, 2017.01.
59. Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M:, PD-L1 expression in papillary renal cell carcinoma., BMC Urol, 17 (1): 8, 2017, 2017.01.
60. Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K, Shiga KI, Koga H, Yamaguchi A, Naito S, Eto M, Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare., BJU Int, 118 (6): 880-884, 2016, 2016.12.
61. Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T, C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy., Oncol Lett, 12 (5): 3995-4000, 2016, 2016.11.
62. Shiota M, Yokomizo A, Takeuchi A, Inokuchi J, Tatsugami K, Ohga S, Sasaki T, Nakamura K, Honda H, Eto M, Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer., Jpn J Clin Oncol, 46 (10): 952-957, 2016, 2016.10.
63. Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Eto M, et al., Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan., J Infect Chemother, 22 (9): 581-586, 2016, 2016.09.
64. Miyazato M, Oshiro T, Saito S, Takahashi R, Eto M, Nishi H, Fujimoto N, Sumino Y, Miyata H, Arai K, Kinjo T, Effects of switching from alpha-blocker to tadalafil in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (KYU-PRO STUDY)., Nishinihon J Urol, 78: 398-405, 2016, 2016.08.
65. Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A, Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2., Cancer Sci, 107 (7): 1022-1028, 2016, 2016.07.
66. Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K,, Nakamura T, Ogawa O, Naito S, Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy., Cancer Sci, 107 (7): 1013-1017, 2016, 2016.07.
67. Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism., Prostate Cancer Prostatic Dis, 19 (2): 191-196, 2016, 2016.06.
68. Masaoka H, Ito H, Soga N, Hosono S, Oze I, Watanabe M, Tanaka H, Yokomizo A, Hayashi N, Eto M, Matsuo K, Aldehyde dehydrogenase 2 (ALDH2) and alcohol dehydrogenase 1B (ADH1B) polymorphisms exacerbate bladder cancer risk associated with alcohol drinking: gene-environment interaction., Carcinogenesis, 37 (6): 583-588, 2016, 2016.06.
69. Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Kashiwagi E, Kiyoshima K, Inokuchi J, Takahashi R, Yokomizo A, Ohara N, Yoshikai Y, Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer., Int Immunopharmacol, 35: 327-331, 2016, 2016.06.
70. Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Ohyama C, Nishiyama H, Fujisawa M, Uemura H, Fujimoto H, Suzuki K, Eto M, et al., Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association., Jpn J Clin Oncol, 46 (5): 468-474, 2016, 2016.05.
71. Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M, Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma., Cancer Sci, 107 (5): 700-707, 2016, 2016.05.
72. Inokuchi J, Seiji Naito, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C, Cancer Registration Committee of the Japanese Urological Association, Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association., Int J Urol, 23 (3): 224-230, 2016, 2016.03.
73. Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, et al., The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery., World J Urol, 34 (3): 347-352, 2016, 2016.03.
74. Motoshima T, Komohara Y, Horlad H, Tsukamoto H, Fujita M, Saito Y, Tanoue K, Kasejima Y, Sugiyama Y, Kawano Y, Nishimura Y, Takeya M, Eto M, CXCL10 and CCL2 mRNA expression in monocytes is inversely correlated with the HLA-DR lower fraction of monocytes in patients with renal cell carcinoma., Oncol Lett, 11 (3): 1911-1916, 2016, 2016.03.
75. Shiota M, Eto M, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer., Int J Urol, 23 (5): 360-369, 2016, 2016.03.
76. Kiyoshima K, Akitake M, Shiota M, Takeuchi A, Takahashi R, Inokuchi J, Tatsugami K, Yokomizo A, Eto M, Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer., Anticancer Res, 36 (2): 799-802, 2016, 2016.02.
77. Shiota M, Yokomizo A, Eto M, Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy., Front Oncol, 5 :304, 2016, 2016.01.
78. Noguchi M, Matsumoto K, Uemura H, Arai G, Eto M, Naito S, Ohyama C, Nasu Y, Tanaka M, Moriya F, Suekane S, Matsueda S, Komatsu N, Sasada T, Yamada A, Kakuma T, Itoh K, An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy., Clin Cancer Res, 22 (1): 54-60, 2016, 2016.01.
79. Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E, Hinotsu S, Cancer Registration Committee of the Japanese Urological Association, Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association., Int J Urol, 22 (11): 1013-1020, 2015, 2015.11.
80. Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, Cancer Registration Committee of the Japanese Urological Association, Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database., Int J Urol, 22 (11): 1023-1027, 2015, 2015.11.
81. Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S, Japan RCC Trialist Collaborative Group (JRTCG) investigators, Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan., BMC Cancer, 15: 667, 2015, 2015.10.
82. Kanayama HO, Fukumori T, Fujimoto H, Nakanishi H, Ohyama C, Suzuki K, Nishiyama H, Eto M, Miki T, Kamoi K, Kubota Y, Takahashi S, Homma Y, Naito S, Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: The first large-scale multicenter study from the Cancer Registration Committee of the Japanese Urological Association., Int J Urol, 22 (9): S1-S7, 2015, 2015.09.
83. Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S, Akaza H, Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma., Ann Oncol, 26 (9): 1871-1876, 2015, 2015.09.
84. Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S, Japanese Society of Renal Cancer, Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era., Int J Urol, 22 (8): 736-740, 2015 , 2015.08.
85. Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M, Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells., Oncol Rep, 33 (6): 2947-2953, 2015, 2015.06.
86. Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, Kikuchi K, Imamura T, Eto M, C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways., Oncol Rep, 33 (4): 1844-1850, 2015, 2015.04.
87. Eto M, IJU this issue., Int J Urol, 22 (3): 241, 2015, 2015.03.
88. Takeuchi A, Eto M, Tatsugami K, Yamada H, Yokomizo A, Shiota M, Itsumi M, Inokuchi J, Kiyoshima K, Dejima T, Imada K, Naito S, Yoshikai S, Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation., Transpl Immunol, 32 (2): 131-139, 2015, 2015.03.
89. Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA., C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells., Prostate, 57:66-79, 2003.09.
90. Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW., Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions., J. Immunol, 169 (5): 2390-2396, 2002, 2002.09.
91. Okano S, Eto M, Tomita Y, Yoshizumi T, Yamada H, Minagawa R, Nomoto K, Sugimachi K, Nomoto K., Cyclophosphamide-induced tolerance in rat orthotopic liver transplantation., Transplantation, 71 (3): 447-456, 2001
, 2001.02.
92. Eto M, Harada M, Tamada K, Tokuda N, Koikawa Y, Nakamura M, Nomoto K, Naito S., Antitumor activity of interleukin-12 against murine bladder cancer., J. Urol, 163 (5): 1549-1552, 2000
, 2000.05.
93. Omoto K, Y-Y Kong, Nomoto K, Umesue M, Murakami Y, Eto M, Nomoto K, Sensitization of T cell receptor-αβ+ T cells recovered from long-term T cell receptor-downmodulation., Immunology, 88: 230-237, 1996.06.
94. Iwatsubo E, Sakamoto Y, Eto M, Kumazawa J, Role of the transversus perinei profundus muscle on voiding: the meaning of UPmax in patients with paralyzed urethral sphincter., Neurourol Urodyn, 15: 169-175, 1996.01.
95. Nishimura Y, Eto M, Maeda T, Hiromatsu K, Nomoto K, Y-Y Kong, Nomoto K, The induction of skin xenograft tolerance in rat-to-mouse combination could be affected by DFR mediating cells and antibodies against rat bone marrow cells as well as NK cells in the cyclophosphamide-induced tolerance system., Immunobiol, 193 (5): 420-438, 1995.08.
96. Eto M, Nishimura Y, Matsuo K, Omoto K, Goto K, Kumazawa J, Nomoto K, Prolongation of kidney graft survival by cyclophosphamide-induced tolerance in rats., J Urol, 153: 1693-1696, 1995.05.
97. Maeda T, Eto M, T Lin, Nishimura Y, Y-Y Kong, Nomoto K, Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-T cell receptor antibody., J Immunol, 153: 4311-4320, 1994.11.
98. Nishimura Y, Eto M, Maeda T, Hiromatsu K, Kobayashi N, Nomoto K, Y-Y Kong, Nomoto K, Inhibition of skin xenograft rejetion by depleting T-cell receptor αβ-bearing cells without T-cell receptor γδ-bearing cells or natural killer cells by monoclonal antibody., Immunology, 83: 196-204, 1994.10.
99. Eto M, Nishimura Y, Y-Y Kong, Maeda T, Nomoto K, Kumazawa J, Nomoto K, Importance of intrathymic mixed chimerism for maintenace of skin allograft tolerance aross fully allogeneic (entire major H-2 plus multiminor histocompatibility) antigen barriers in mice., Transplant Proc, 26 (2): 841-844, 1994.04.
100. Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, Nomoto K, Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody., Arthritis & Rheumatism, 37 (3): 406-413, 1994.03.
101. Maeda T, Eto M, Nishimura Y, Y-Y Kong, Nomoto K, Nomoto K, Evidence that donor-specific suppressor T cells can be produced indepently of the thymus., Transplantation, 57 (3): 461-463, 1994.02.
102. Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Y-Y Kong, Kubo RT, Kumazawa J, Nomoto K, Inhibition of allograft rejection by anti-T-cell receptor-αβ monoclonal antibodies preserving resistance to bacterial infection., Immunology, 81: 198-204, 1994.02.
103. Maeda T, Eto M, Nishimura Y, Nomoto K, Y-Y Kong, Nomoto K, Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice., J Immunol, 150 (3): 753-762, 1993.02.
104. Maeda T, Eto M, Nishimura Y, Nomoto Y, Y-Y Kong, Nomoto K, Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming., Immunology, 78: 113-121, 1993.01.